Ikaria licenses cardiac therapy from BioLineRx
This article was originally published in Scrip
Executive Summary
Ikaria has obtained a worldwide exclusive licence to BioLineRx’s BL-1040, a potential treatment for preventing cardiac damage following a heart attack, for up to $282.5 million.